APN (APN) News
Follow APN (APN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Panmure Liberum proposes secondary placing in Applied Nutrition
Panmure Liberum Limited said it has applied for a proposed secondary placing in Applied Nutrition. The notice is an RNS and includes standard jurisdictional restrictions on release and distribution.
EQUITY | Sep 10, 2026, 03:48 PM UTC
H
Aspen expects Mounjaro Africa sales above $124 million in current year
Aspen Pharmacare expects African sales of Eli Lilly’s Mounjaro to exceed 2 billion rand (about $124 million) in its current financial year, citing strong South Africa demand and planned launches in Nigeria and Kenya.
EARNINGS | Sep 03, 2026, 12:36 PM UTC
L
APN sets FY 2027 targets: ZAR 9bn+ EBITDA and 50%+ NHEPS growth
Aspen Pharmacare says it delivered strong EBITDA and NHEPS growth despite flat revenue. It targets FY 2027 EBITDA over ZAR 9 billion, 50%+ NHEPS growth, and robust free cash flow, prioritizing share buybacks.
EARNINGS | Sep 03, 2026, 09:20 AM UTC
L
APN raises FY 2027 guidance: EBITDA above ZAR 9bn, NHEPS growth over 50%
Aspen Pharmacare (APN) raised FY 2027 guidance, targeting EBITDA over ZAR 9 billion and NHEPS growth above 50%, alongside stronger free cash flow.
EARNINGS | Sep 03, 2026, 08:13 AM UTC
L
Aspen Pharmacare results lift EBITDA and NHEPS on efficiency, APAC divestment
Aspen Pharmacare reported strong EBITDA and NHEPS growth with flat revenue, citing Commercial Pharma and efficiency gains. APAC divestment unlocked value, strengthened the balance sheet, and GLP-1s plus Sterile FDF are s
EARNINGS | Sep 03, 2026, 06:43 AM UTC
H
Aspen Pharmacare annual normalised earnings rise 22% on Mounjaro demand
Aspen Pharmacare (APN) reported annual normalised earnings up 22%, citing strong demand for obesity and diabetes treatment Mounjaro it distributes and improving profitability in its manufacturing business.
EARNINGS | Sep 02, 2026, 12:29 PM UTC
L
APN normalised EPS from continuing ops rises 28% on improved outlook
APN said normalised headline EPS from continuing operations grew 28% at constant exchange rates, backed by stronger Commercial Pharmaceuticals and Manufacturing EBITDA. It also cited an APAC divestment unlocking R28 bill
EARNINGS | Sep 02, 2026, 11:54 AM UTC
L
Aspen Pharmacare normalised earnings rise 22%, HEPS to 801.5 cents
Aspen Pharmacare reported a 22% rise in normalised earnings, with normalised headline HEPS increasing to 801.5 cents. Growth was supported by strong momentum in its commercial pharmaceuticals unit during the reporting pe
EARNINGS | Sep 02, 2026, 11:23 AM UTC
L
Broker tips: Chesnara, Applied Nutrition, Softcat, Bytes Technology
Broker tips: Chesnara, Applied Nutrition, Softcat, Bytes Technology
RATES | Aug 26, 2026, 03:09 PM UTC
L
Canaccord Genuity raises Applied Nutrition target price
TradingView News says Canaccord Genuity has raised its target price for Applied Nutrition.
EQUITY | Aug 26, 2026, 01:40 PM UTC
L
dpa-AFX Overview: Analyst recommendations on U.K. stocks
dpa-AFX Overview: Analyst recommendations on U.K. stocks
EQUITY | Aug 26, 2026, 09:18 AM UTC
L
Applied Nutrition lifts FY outlook, cites sustained demand
Applied Nutrition lifts FY outlook, cites sustained demand
EQUITY | Aug 26, 2026, 08:44 AM UTC